The FDA has approved aprocitentan (Tryvio), making it the first endothelin receptor antagonist for the treatment of high blood pressure (BP), Idorsia Pharmaceuticals announced on Wednesday. The ...
The study found no significant differences between the groups in terms of disease progression, morbidity or mortality, or all-cause death. Macitentan demonstrated superiority over other endothelin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results